Drug Profile
Ezetimibe/simvastatin - Merck & Co
Alternative Names: Inegy; MK-0653A; Simvastatin/ezetimibe; Vytorin; Zetia™/Zocor®; Zintrepid; Zocor®/Zetia™Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck/Schering-Plough Pharmaceuticals
- Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Naphthalenes; Propanols; Small molecules
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute coronary syndromes; Hypercholesterolaemia; Hyperlipidaemia
- Discontinued Aortic valve stenosis